Carlos Martín Restrepo

Carlos Martín Restrepo

Auto-generated profile, based on publicly available information

Carlos Martín Restrepo

School of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), Universidad del Rosario

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2015 in Nature Genetics
Verified
Journal Article
Open access
PDF file
YCYa-Chun Chen
Ya-Chun Chen
MAMichaela Auer-Grumbach
Michaela Auer-Grumbach
SMShinya Matsukawa
Shinya Matsukawa
MZManuela Zitzelsberger
Manuela Zitzelsberger
ATAndreas C Themistocleous
Andreas C Themistocleous
JSJan Senderek
Jan Senderek
Geoffrey Woods, Jan Senderek and colleagues show that biallelic mutations in PRDM12 cause congenital insensitivity to pain. They further show that PRDM12 is expressed in nociceptors and their progenitors and participates in sensory neuron development in Xenopus. Pain perception has evolved as a warning mechanism to alert organisms to tissue damage and dangerous environments1,2. In humans, however, undesirable, excessive or chronic pain is a common and major societal burden for which available medical treatments are currently suboptimal3,4. New therapeutic options have recently been derived from studies of individuals with congenital insensitivity to pain (CIP)5,6. Here we identified 10 different homozygous mutations in PRDM12 (encoding PRDI-BF1 and RIZ homology domain-containing protein 12) in subjects with CIP from 11 families. Prdm proteins are a family of epigenetic regulators that control neural specification and neurogenesis7,8. We determined that Prdm12 is expressed in nociceptors and their progenitors and participates in the development of sensory neurons in Xenopus embryos. Moreover, CIP-associated mutants abrogate the histone-modifying potential associated with wild-type Prdm12. Prdm12 emerges as a key factor in the orchestration of sensory neurogenesis and may hold promise as a target for new pain therapeutics9,10.

2 May 2012 in Human Mutation
Verified
Journal Article
Closed access
PDF file
CDChristine P. Diggle
Christine P. Diggle
David ParryDavid Parry
David Parry
CLClare V. Logan
Clare V. Logan
PLPaul Laissue
Paul Laissue
CRCarolina Rivera
Carolina Rivera
DBDavid Bonthron
David Bonthron
Pachydermoperiostosis, or primary hypertrophic osteoarthropathy (PHO), is an inherited multisystem disorder, whose features closely mimic the reactive osteoarthropathy that commonly accompanies neoplastic and inflammatory pathologies. We previously described deficiency of the prostaglandin‐degrading enzyme 15‐hydroxyprostaglandin dehydrogenase (HPGD) as a cause of this condition, implicating elevated circulating prostaglandin E2 (PGE2) as causative of PHO, and perhaps also as the principal mediator of secondary HO. However, PHO is genetically heterogeneous. Here, we use whole‐exome sequencing to identify recessive mutations of the prostaglandin transporter SLCO2A1, in individuals lacking HPGD mutations. We performed exome sequencing of four probands with severe PHO, followed by conventional mutation analysis of SLCO2A1 in nine others. Biallelic SLCO2A1 mutations were identified in 12 of the 13 families. Affected individuals had elevated urinary PGE2, but unlike HPGD‐deficient patients, also excreted considerable quantities of the PGE2 metabolite, PGE‐M. Clinical differences between the two groups were also identified, notably that SLCO2A1‐deficient individuals have a high frequency of severe anemia due to myelofibrosis. These findings reinforce the key role of systemic or local prostaglandin excess as the stimulus to HO. They also suggest that the induction or maintenance of hematopoietic stem cells by prostaglandin may depend upon transporter activity. Hum Mutat 33:1175–1181, 2012.

8 February 2006 in Human Mutation
Verified
Journal Article
Open access
PDF file
AFAfrica Fernandez-L
Africa Fernandez-L
FSFrancisco Sanz-Rodriguez
Francisco Sanz-Rodriguez
RZRoberto Zarrabeitia
Roberto Zarrabeitia
APAlfonso Perez-Molino
Alfonso Perez-Molino
CMCarmelo Morales
Carmelo Morales
Luisa L BotellaLuisa L Botella
Luisa L Botella
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant and age‐dependent vascular disorder originated by mutations in Endoglin (ENG) or activin receptor‐like kinase‐1 (ALK1, ACVRL1) genes. The first large series HHT analysis in Spanish population has identified mutations in 17 unrelated families. Ten different mutations in ALK1 and six in ENG genes were found. Six unrelated families had a mutation in ENG gene, four representing new mutations, p.Y258fs, pV323fs, p.F279fs (c.834_837del CTTC), and p.F279fsdupC. Eleven unrelated families harboured mutations in ALK1; ten were new mutations identified as p.H328P, p.R145fs, p.G68C, p.A377T, p.H297R, p.M376T, p.C36Y, p.H328P, p.T82del and p.R47P. Overall, ALK1 mutations (HHT2) were predominant over ENG mutations (HHT1), in agreement with data reported for other Mediterranean countries (France, Italy), but at variance with Northern Europe or North America. Endoglin expression in HHT1 or HHT2 activated monocytes and blood outgrowth endothelial cells (BOECs) from older patients was well below the theoretical 50% level expected from the HHT1 haploinsufficiency model, suggesting that the pathogenic endoglin haploinsufficiency leading to the HHT phenotype is age‐dependent. Interestingly, ALK1 protein levels of HHT BOECs in some missense ALK1 mutants were similar to controls. In vitro expression of these ALK1 constructs suggests that, in addition to the haploinsufficiency model, certain ALK1 mutants may inhibit the function of the wild type allele.

7 May 2019 in Genes
Verified
Journal Article
Open access
PDF file
HYHernan Yupanqui-Lozno
Hernan Yupanqui-Lozno
RBRaul Bastarrachea
Raul Bastarrachea
MYMaria E. Yupanqui-Velazco
Maria E. Yupanqui-Velazco
MAMonica Alvarez
Monica Alvarez
EMEsteban Medina-Méndez
Esteban Medina-Méndez
LRLuis Gustavo Celis Regalado
Luis Gustavo Celis Regalado
Background: Congenital leptin deficiency is a recessive genetic disorder associated with severe early-onset obesity. It is caused by mutations in the leptin (LEP) gene, which encodes the protein product leptin. These mutations may cause nonsense-mediated mRNA decay, defective secretion or the phenomenon of biologically inactive leptin, but typically lead to an absence of circulating leptin, resulting in a rare type of monogenic extreme obesity with intense hyperphagia, and serious metabolic abnormalities. Methods: We present two severely obese sisters from Colombia, members of the same lineal consanguinity. Their serum leptin was measured by MicroELISA. DNA sequencing was performed on MiSeq equipment (Illumina) of a next-generation sequencing (NGS) panel involving genes related to severe obesity, including LEP. Results: Direct sequencing of the coding region of LEP gene in the sisters revealed a novel homozygous missense mutation in exon 3 [NM_002303.3], C350G>T [p.C117F]. Detailed information and clinical measurements of these sisters were also collected. Their serum leptin levels were undetectable despite their markedly elevated fat mass. Conclusions: The mutation of LEP, absence of detectable leptin, and the severe obesity found in these sisters provide the first evidence of monogenic leptin deficiency reported in the continents of North and South America.

27 July 2015 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
OOOscar Ortega-Recalde
Oscar Ortega-Recalde
OBO.I. Beltrán
O.I. Beltrán
JGJ.M. Gálvez
J.M. Gálvez
APA. Palma‐Montero
A. Palma‐Montero
CRC.M. Restrepo
C.M. Restrepo
PLP. Laissue
P. Laissue

5 March 2015 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
MCMauricio De Castro
Mauricio De Castro
CRCarlos Martín Restrepo
Carlos Martín Restrepo
Genetics and Genomic medicine in Colombia.